Sort
10,766 grants matching “checkpoint inhibitor”
Augmenting Quadruple Negative Breast Cancer Treatment by ADRM1 Inhibitor Up284
$350,627Balasubramanyam Karanam · Tuskegee University · U54 · FY2025 · MD
Project 1: Targeting Metabolic Vulnerabilities in Lung Cancer
$350,616Ralph J Deberardinis · Ut Southwestern Medical Center · P50 · FY2024 · CA
Poisoning of PARP and Topoisomerase I to Treat Ovarian Cancer
$350,594Scott H Kaufmann · Mayo Clinic Rochester · P50 · FY2012 · CA
Replication Stress Sensing and Signaling Defects in SCLC
$350,490John Thomas Poirier · New York University School Of Medicine · P01 · FY2025 · CA
Replication Stress Sensing and Signaling Defects in SCLC
$350,490John Thomas Poirier · New York University School Of Medicine · P01 · FY2024 · CA
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
$350,460Kian H Lim · Washington University · R37 · FY2023 · CA
Checkpoints of TNF Gene Regulation
$350,390Anne Goldfeld · Immune Disease Institute, Inc. · R01 · FY2006 · GM
GENETIC ANALYSIS OF CHROMOSOME 9P21 IN ORAL CARCINOMA
$350,335University Of Pittsburgh At Pittsburgh · R01 · FY2000 · DE
Structural Determinants in Cell Growth Control by p21 and p27
$350,281Richard W Kriwacki · St. Jude Children'S Research Hospital · R01 · FY2007 · CA
MECHANISMS OF RADIORESISTANCE AND CELL CYCLE PROGRESSION
$350,262Columbia University Health Sciences · R01 · FY2001 · GM
Project 2: Determinants of Response and Resistance to DNA-Damaging Radiation Plus Immunotherapy Combinations in Triple Negative Breast Cancer
$350,219Gaorav P. Gupta · Univ Of North Carolina Chapel Hill · P50 · FY2025 · CA
Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit
$350,164Meredith A Morgan · University Of Michigan At Ann Arbor · R01 · FY2016 · CA
Synthesis and evaluation of BTN3A1 ligands for cancer immunotherapy
$350,029Andrew J Wiemer · University Of Connecticut Storrs · R01 · FY2022 · CA
Novel injectable implants for long-term local controlled release of therapeutic monoclonal antibodies
$350,027Vishalakshi Krishnan · Asko Therapeutics, Inc. · R43 · FY2025 · GM
USC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center
$350,001Lily Dara · University Of Southern California · U01 · FY2025 · DK
Mechanisms of selective therapeutic synergy of PARP-inhibition and CTLA4 blockade engaged by interferon-gamma in the ovarian tumor microenvironment
$349,981Sarah Foster Adams · University Of New Mexico Health Scis Ctr · R37 · FY2022 · CA
Combining senescence-inducing and senolytic agents to improve melanoma therapy
$349,980Anna E Vilgelm · Ohio State University · R37 · FY2021 · CA
Targeting Chronic ER Stress in T Cells to Improve Cancer Immunotherapy
$349,947Jessica E Thaxton · Univ Of North Carolina Chapel Hill · R01 · FY2022 · CA
Nanoformulated small molecule immunotherapy for SHH medulloblastoma
$349,875Marina Sokolsky-Papkov · Univ Of North Carolina Chapel Hill · R01 · FY2025 · NS
Macrophage-based Therapy and Immune Checkpoint Blockade for Glioblastoma
$349,874Shideng Bao · Cleveland Clinic Lerner Com-Cwru · R01 · FY2024 · CA
Single-Cell, Spatial and Functional Dissection of Cancer Cell States, Co-Evolving Ecosystems, and Vulnerabilities During Tumor Progression and Metastasis
$349,808Benjamin Izar · Columbia University Health Sciences · U54 · FY2024 · CA
Targeting cholesterol metabolism and replication stress response in cancer therapy
$349,713Junran Zhang · Ohio State University · R01 · FY2022 · CA
Strategies to Disrupt Oncogenic Transcription in RCC Tumors
$349,713Chunling Yi · Georgetown University · R01 · FY2022 · CA
B55 alpha deficiency as a therapeutic target in cancer
$349,713Junran Zhang · Ohio State University · R01 · FY2022 · CA
Strategies to Disrupt Oncogenic Transcription in RCC Tumors
$349,713Chunling Yi · Georgetown University · R01 · FY2023 · CA